Medication safety and chronic kidney disease in older adults prescribed metformin: a cross-sectional analysis

BMC Nephrology

Bessie A Young³  Itamar B Abrass¹  Deborah L Huang² 

[1] Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA;Division of General Internal Medicine, University of Washington, Box 354765, 4245 Roosevelt Way NE, Seattle, WA 98105, USA;Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA, USA

关键词: Renal insufficiency;    Metformin;    Medication safety;    Drug prescriptions;    Diabetes mellitus;    Chronic kidney disease;    Aged;   

Others  :  1082676
DOI  :  10.1186/1471-2369-15-86

 received in 2013-12-31, accepted in 2014-05-01,  发布年份 2014

【 摘 要 】

Background

Medication safety in patients with chronic kidney disease (CKD) is a growing concern. This is particularly relevant in older adults due to underlying CKD. Metformin use is contraindicated in patients with abnormal kidney function; however, many patients are potentially prescribed metformin inappropriately. We evaluated the prevalence of CKD among older adults prescribed metformin for type 2 diabetes mellitus using available equations to estimate kidney function and examined demographic characteristics of patients who were potentially inappropriately prescribed metformin.

Methods

We conducted a cross-sectional analysis of older adults aged ≥65 years prescribed metformin from March 2008-March 2009 at an urban tertiary-care facility in Seattle, Washington, USA. CKD was defined using National Kidney Foundation-Kidney Disease Outcomes Quality Initiative criteria. Creatinine clearance was calculated using the Cockcroft-Gault equation; estimated glomerular filtration rate was calculated using the abbreviated Modification of Diet in Renal Disease (MDRD) and CKD-Epidemiology (EPI) Collaboration equations. Regression analyses were used to determine the associations between demographic characteristics and prevalent CKD.

Results

Among 356 subjects (median age 69 years, 52.5% female, 39.4% non-Hispanic black), prevalence of stage 3 or greater CKD calculated by any of the equations was 31.4%. The Cockcroft-Gault equation identified more subjects as having CKD (23.7%) than the abbreviated MDRD (21.1%) or CKD-EPI (21.7%) equations (P < 0.001). Older age (OR = 1.13, 95% CI 1.08-1.19) and female sex (OR = 2.51, 95% CI 1.44-4.38) were associated with increased odds of potentially inappropriate metformin prescription due to CKD; non-Hispanic black race was associated with decreased odds of potentially inappropriate metformin prescription due to CKD (OR = 0.41, 95% CI 0.23-0.71).

Conclusions

CKD is common in older adults prescribed metformin for type 2 diabetes, raising concern for potentially inappropriate medication use. No single equation to estimate kidney function may accurately identify CKD in this population. Medication safety deserves greater consideration among elderly patients due to the widespread prevalence of CKD.

【 授权许可】

   
2014 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145(4):247-254.
• [2]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612.
• [3]Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16(1):31-41.
• [4]Dowling TC, Matzke GR, Murphy JE, Burckart GJ: Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacotherapy 2010, 30(8):776-786.
• [5]Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):2038-2047.
• [6]National chronic kidney disease fact sheet: general information and national estimates on chronic kidney disease in the United States 2010. http://www.cdc.gov/diabetes/pubs/pdf/kidney_Factsheet.pdf webcite
• [7]American Geriatrics Society Expert Panel on the Care of Older Adults with Diabetes Mellitus: Guidelines abstracted from the American geriatrics society guidelines for improving the care of older adults with diabetes mellitus: 2013 update. J Am Geriatr Soc 2013, 61(11):2020-2026.
• [8]Metformin hydrochloride Greenwood Village, CO: Truven Health Analytics; 2013:1978-2013.
• [9]Basow DS: Metformin: drug information. Waltham, MA: UpToDate; 2013.
• [10]Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010., 4CD002967
• [11]Kidney disease outcomes quality initiative: clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 4: definition and classification of stages of chronic kidney disease, guideline 1: definition and stages of chronic kidney disease http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm webcite
• [12]Roberts GW, Ibsen PM, Schiøler CT: Modified diet in renal disease method overestimates renal function in selected elderly patients. Age Ageing 2009, 38(6):698-703.
• [13]Gill J, Malyuk R, Djurdjev O, Levin A: Use of GFR equations to adjust drug doses in an elderly multi-ethnic group – a cautionary tale. Nephrol Dial Transplant 2007, 22(10):2894-2899.
• [14]Christensson A, Elmståhl S: Estimation of the age-dependent decline of glomerular filtration rate from formulas based on creatinine and cystatin C in the general elderly population. Nephron Clin Pract 2011, 117(1):c40-c50.
• [15]Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-Connell AT, Bakris GL, McCullough PA: Comparison of the CKD epidemiology collaboration (CKD-EPI) and modification of diet in renal disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the kidney early evaluation program (KEEP). Am J Kidney Dis 2011, 57(3 Suppl 2):S9-S16.
• [16]Pedone C, Corsonello A, Incalzi RA, GIFA Investigators: Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006, 35(2):121-126.
• [17]Spruill WJ, Wade WE, Cobb HHR: Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother 2008, 6(3):153-160.
• [18]Lipska KJ, Bailey CJ, Inzucchi SE: Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011, 34(6):1431-1437.
• [19]Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, Brown WW, Burrows NR, Jurkovitz CT, McFarlane SI, Norris KC, Shlipak M, Whaley-Connell AT, Chen SC, Bakris GL, McCullough PA: Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the kidney early evaluation program (KEEP). Am J Kidney Dis 2010, 55(3 Suppl 2):S23-S33.
• [20]Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, Kalra PA, O’Donoghue DJ, New JP: The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006, 21(1):88-92.
• [21]Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 2003, 41(1):1-12.
• [22]New JP, Middleton RJ, Klebe B, Farmer CK, de Lusignan S, Stevens PE, O’Donoghue DJ: Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med 2007, 24(4):364-369.
• [23]Watanabe Y, Fujii H, Aoki K, Kanazawa Y, Miyakawa T: A cross-sectional survey of chronic kidney disease and diabetic kidney disease in Japanese type 2 diabetic patients at four urban diabetes clinics. Intern Med 2009, 48(6):411-414.
• [24]Schorr M, Hemmelgarn BR, Tonelli M, Soo A, Manns BJ, Bresee LC: Assessment of serum creatinine and kidney function among incident metformin users. Can J Diabetes 2013, 37(4):226-230.
• [25]Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K: Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012, 156(11):785-795.
• [26]Ekström N, Schiöler L, Svensson AM, Eeg-Olofsson K, Miao Jonasson J, Zethelius B, Cederholm J, Eliasson B, Gudbjörnsdottir S: Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish national diabetes register. BMJ Open 2012, 2(4):e001076.
• [27]Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR: Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case–control analysis. Diabetes Care 2008, 31(11):2086-2091.
• [28]Kamber N, Davis WA, Bruce DG, Davis TM: Metformin and lactic acidosis in an Australian community setting: the fremantle diabetes study. Med J Aust 2008, 188(8):446-449.
• [29]Vasisht KP, Chen SC, Peng Y, Bakris GL: Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab 2010, 12(12):1079-1083.